TELO FY 2022 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

TELOTelomir Pharmaceuticals, Inc. Common Stock

$46M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$854,147

Net Income

-$854,147

EPS (Diluted)

$-0.03

Cash Flow

Operating Cash Flow

-$468,661

Free Cash Flow

-$468,661

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$48,730

Total Liabilities

$986,008

Stockholders' Equity

-$937,278

Cash & Equivalents

$1,419

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$854,147	-$138,131	-518.4%
Net Income	-$854,147	-$138,131	-518.4%